These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

77 related articles for article (PubMed ID: 18606594)

  • 1. Oral vinorelbine as first line chemotherapy in unfit elderly patients with hormone-refractory prostate cancer.
    Caristi N; Maisano R; Iorfida M; Scimone A; Lupo G; Buda C; Scisca C; Adamo V
    J Chemother; 2008 Jun; 20(3):368-73. PubMed ID: 18606594
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dose escalation of oral vinorelbine in combination with estramustine in hormone-refractory adenocarcinoma of the prostate.
    Mackler NJ; Dunn RL; Hellerstedt B; Cooney KA; Fardig J; Olson K; Pienta KJ; Smith DC
    Cancer; 2006 Jun; 106(12):2617-23. PubMed ID: 16691618
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase II trial of vinorelbine and estramustine in the treatment of metastatic hormone-resistant prostate cancer.
    Borrega P; Velasco A; Bolaños M; del Mar Perez M; Mel JR; Reina JJ; Rodríguez-Jaraiz MA; Chaves M; González-Barón M
    Urol Oncol; 2004; 22(1):32-5. PubMed ID: 14969801
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Randomised phase III study of intravenous vinorelbine plus hormone therapy versus hormone therapy alone in hormone-refractory prostate cancer.
    Abratt RP; Brune D; Dimopoulos MA; Kliment J; Breza J; Selvaggi FP; Beuzeboc P; Demkow T; Oudard S
    Ann Oncol; 2004 Nov; 15(11):1613-21. PubMed ID: 15520061
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase II study of estramustine, oral etoposide, and vinorelbine in hormone-refractory prostate cancer.
    Colleoni M; Graiff C; Vicario G; Nelli P; Sgarbossa G; Pancheri F; Manente P
    Am J Clin Oncol; 1997 Aug; 20(4):383-6. PubMed ID: 9256895
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Weekly docetaxel and vinorelbine (VIN-DOX) as first line treatment in patients with hormone refractory prostate cancer.
    Di Lorenzo G; Pizza C; Autorino R; De Laurentiis M; Marano O; D'Alessio A; Cancello G; Altieri V; Tortora G; Perdonà S; Bianco AR; De Placido S
    Eur Urol; 2004 Dec; 46(6):712-6. PubMed ID: 15548437
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase II study of vinorelbine in patients with androgen-independent prostate cancer.
    Oudard S; Caty A; Humblet Y; Beauduin M; Suc E; Piccart M; Rolland F; Fumoleau P; Bugat R; Houyau P; Monnier A; Sun X; Montcuquet P; Breza J; Novak J; Gil T; Chopin D
    Ann Oncol; 2001 Jun; 12(6):847-52. PubMed ID: 11484963
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Intravenous vinorelbine as first line chemotherapy in patients with castration-resistant prostate cancer].
    Grenader T; Plotkin Y; Rosengarten O
    Harefuah; 2014 Dec; 153(12):731-4, 752. PubMed ID: 25654915
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Docetaxel, vinorelbine, and zoledronic acid as first-line treatment in patients with hormone refractory prostate cancer: a phase II study.
    Di Lorenzo G; Autorino R; Perdonà S; De Laurentiis M; D'Armiento M; Cancello G; Mirone V; Imbimbo C; Longo N; Altieri V; Tortora G; Figg WD; De Placido S
    Eur Urol; 2007 Oct; 52(4):1020-7. PubMed ID: 17360103
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characterization of prognostic factors and efficacy in a phase-II study with docetaxel and estramustine for advanced hormone refractory prostate cancer.
    Nelius T; Reiher F; Lindenmeir T; Klatte T; Rau O; Burandt J; Filleur S; Allhoff EP
    Onkologie; 2005 Nov; 28(11):573-8. PubMed ID: 16249643
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vinorelbine, doxorubicin, and prednisone in androgen-independent prostate cancer.
    Borden LS; Clark PE; Lovato J; Hall MC; Stindt D; Harmon M; M Mohler R; Torti FM
    Cancer; 2006 Sep; 107(5):1093-100. PubMed ID: 16888761
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combination chemotherapy with docetaxel, vinorelbine and estramustine phosphate in metastatic androgen-resistant prostate cancer: a single institution experience.
    Pectasides D; Pectasides E; Papaxoinis G; Koumarianou A; Psyrri A; Xiros N; Tountas N; Kamposioras K; Papatsibas G; Floros T; Gouveris P; Karageorgopoulou S; Economopoulos T
    Anticancer Res; 2009 Feb; 29(2):769-75. PubMed ID: 19331234
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vinorelbine and estramustine in androgen-independent metastatic prostate cancer: a phase II study.
    Smith MR; Kaufman D; Oh W; Guerin K; Seiden M; Makatsoris T; Manola J; Kantoff PW
    Cancer; 2000 Oct; 89(8):1824-8. PubMed ID: 11042579
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Metronomic oral cyclophosphamide prednisolone chemotherapy is an effective treatment for metastatic hormone-refractory prostate cancer after docetaxel failure.
    Ladoire S; Eymard JC; Zanetta S; Mignot G; Martin E; Kermarrec I; Mourey E; Michel F; Cormier L; Ghiringhelli F
    Anticancer Res; 2010 Oct; 30(10):4317-23. PubMed ID: 21036758
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multicenter randomized phase II study of two schedules of docetaxel, estramustine, and prednisone versus mitoxantrone plus prednisone in patients with metastatic hormone-refractory prostate cancer.
    Oudard S; Banu E; Beuzeboc P; Voog E; Dourthe LM; Hardy-Bessard AC; Linassier C; Scotté F; Banu A; Coscas Y; Guinet F; Poupon MF; Andrieu JM
    J Clin Oncol; 2005 May; 23(15):3343-51. PubMed ID: 15738542
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vinorelbine and prednisone in older cancer patients with hormone-refractory metastatic prostate cancer. A phase II study.
    Tralongo P; Bollina R; Aiello R; Di Mari A; Moruzzi G; Beretta G; Mauceri G; Conti G
    Tumori; 2003; 89(1):26-30. PubMed ID: 12729357
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A pilot study of AFL-T (doxorubicin, 5-fluorouracil, leucovorin, and tamoxifen) combination chemotherapy for hormone-refractory prostate cancer.
    Lin CC; Hsu CH; Chen J; Tsai TC; Cheng AL; Pu YS
    Anticancer Res; 2001; 21(2B):1385-90. PubMed ID: 11396219
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase II study of vinorelbine with low dose prednisone in the treatment of hormone-refractory metastatic prostate cancer.
    Robles C; Furst AJ; Sriratana P; Lai S; Chua L; Donnelly E; Solomon J; Sundaram M; Feun L; Savaraj N
    Oncol Rep; 2003; 10(4):885-9. PubMed ID: 12792740
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Docetaxel-based chemotherapy with zoledronic acid and prednisone in hormone refractory prostate cancer: factors predicting response and survival.
    Nayyar R; Sharma N; Gupta NP
    Int J Urol; 2009 Sep; 16(9):726-31. PubMed ID: 19769656
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Low-dose metronomic oral administration of vinorelbine in the first-line treatment of elderly patients with metastatic breast cancer.
    Addeo R; Sgambato A; Cennamo G; Montella L; Faiola V; Abbruzzese A; Capasso E; Leo L; Botti G; Caraglia M; Del Prete S
    Clin Breast Cancer; 2010 Aug; 10(4):301-6. PubMed ID: 20705563
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.